The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mHtt containing expanded polyglutamine (polyQ) tracts increases p53 levels and transcriptional activity in neuronal cells by binding to p53.251”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [251]
In the citing paper
“Affected brain regions in HD patients, HD animal models, and cells overexpressing mHtt present elevated p53 levels.251,255”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [251]
In the citing paper
“inhibition of p53 activity with a small-molecule antagonist of p53, pifithrin-α, or by genetic ablation effectively diminished many of the symptoms in models of these p53-dependent diseases”
From p53 at a glance (2010) · cites this paper as Bae et al., 2005
In the citing paper
“Furthermore, in several neurological disorders, including Alzheimer's, Parkinson's and Huntington's diseases, p53-mediated neuronal apoptosis also contributes to the associated pathologies (Bae et al., 2005; Bretaud et al., 2007; Culmsee and Mattson, 2005; Duan et al., 2002).”
From p53 at a glance (2010) · cites this paper as Bae et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 8×
“Because nuclear p53 regulates many mitochondrial genes and genes for oxidative stress (Sharpless and DePinho, 2002; Vogelstein et al., 2000), we hypothesized that p53 might link the nuclear and mitochondrial pathologies in HD.”
BackgroundInfluentialMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“The increased p53 occurs selectively in the P1 fractions designated as crude nuclei (Figure 1A) in 1% SDS-soluble, nonaggregate fractions (Figure 1C), implying that the transactivation-independent role for p53 in the mitochondria is unlikely (Chipuk et al., 2004).”
BackgroundDefinition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Cited by
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,603
Telomere dysfunction induces metabolic and mitochondrial compromise
Sahin, E., Colla, S., Liesa, M., Moslehi, J., Müller, F. L., Guo, M., Cooper, M., Kotton, D., Fabian, A. J., Walkey, C., et al. (2011) · Nature · doi:10.1038/nature09787 · Cited by 1,319
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Saudou, F., & Humbert, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.003 · Cited by 951
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Kamath, T., Abdulraouf, A., Burris, S. J., Langlieb, J., Gazestani, V., Nadaf, N. M., Balderrama, K., Vanderburg, C., & Macosko, E. Z. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01061-1 · Cited by 552
Mechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
Trushina, E., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 439
Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508052102 · Cited by 424
Self-citationMitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Brady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
Long non-coding RNAs in Huntington's disease neurodegeneration
Johnson, R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.006 · Cited by 398
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Guo, X., Disatnik, M.-H., Monbureau, M., Shamloo, M., Mochly-Rosen, D., & Qi, X. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70911 · Cited by 370
Brouillet, E., Jacquard, C., Bizat, N., & Blum, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03515.x · Cited by 364
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease
Kim, J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Cormier, K., Smith, K., Beal, M. F., & Ferrante, R. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq306 · Cited by 357
Axis of ageing: telomeres, p53 and mitochondria
Sahin, E., & DePinho, R. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3352 · Cited by 345
White, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026120 · Cited by 320
A microRNA-based gene dysregulation pathway in Huntington's disease
Johnson, R., Zuccato, C., Belyaev, N. D., Guest, D. J., Cattaneo, E., & Buckley, N. J. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.001 · Cited by 312
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Mutant huntingtin and mitochondrial dysfunction
Bossy-Wetzel, E., Petrilli, A., & Knott, A. B. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.09.004 · Cited by 268
Transcriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 268
Altered microRNA regulation in Huntington's disease models
Lee, S.-T., Chu, K., Im, W.-S., Yoon, H.-J., Im, J.-Y., Park, J.-E., Park, K.-H., Jung, K.-H., Lee, S. K., Kim, M., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.10.012 · Cited by 262
Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236
A Review for the Pharmacological Effect of Lycopene in Central Nervous System Disorders
Chen, D., Huang, C., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.151 · Cited by 206
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
Gaughwin, P. M., Ciesla, M., Lahiri, N., Tabrizi, S. J., Brundin, P., & Björkqvist, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr111 · Cited by 145
Ghose, J., Sinha, M., Das, E., Jana, N. R., & Bhattacharyya, N. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023837 · Cited by 98
p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases
Dai, C.-Q., Luo, T.-T., Luo, S.-C., Wang, J.-Q., Wang, S.-M., Bai, Y.-H., Yang, Y.-L., & Wang, Y.-Y. (2016) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-016-9669-5 · Cited by 93
Inositol Polyphosphate Multikinase Is a Coactivator of P53-Mediated Transcription and Cell Death
Xu, R., Sen, N., Paul, B. D., Snowman, A. M., Rao, F., Vandiver, M. S., Xu, J., & Snyder, S. H. (2013) · Science Signaling · doi:10.1126/scisignal.2003405 · Cited by 52
Self-citationSalemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., Snyder, S. H., & Sawa, A.
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 47
- Issue
- 1
- Pages
- 29-41
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W2061258627
- Cited by
- 485
- References
- 72
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.